{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:18:08Z","timestamp":1790032688066,"version":"4.0.1"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To explore the feasibility of delivering community\u2010based drug safety testing (<jats:italic>drug checking<\/jats:italic>), to trial service design characteristics and to compare with festival\u2010based testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In total, 171 substances of concern were submitted on 5 dates at 3 venues in 2 UK cities and tested using up to 6 analytical techniques. Test results and harm reduction advice were distributed directly to over 200 service users through 144 tailored healthcare consultations, to stakeholders, and through early warning systems, media and social media alerts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 171 samples were submitted and identified as MDMA (43.3%), cocaine (12.9%), ketamine (12.9%), various psychedelics submitted by students, and heroin and a synthetic cannabinoid submitted by rough sleeping communities, with 76% of samples' test results as expected. The 144 primary service users identified as 91.7% white, 68.1% male, with an average age of 26.7 years. Reported harm reduction intentions included alerting friends and acquaintances (37.5%), being more careful mixing that substance (35.4%), lowered dosage (27.8%), disposal of further substances (6.9%) and additionally 2.8% handed over further substances for verified destruction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Community\u2010based drug safety testing (<jats:italic>drug checking<\/jats:italic>) was piloted for the first time in the UK\u2014within a drugs service, a community centre and a church\u2014with consideration given to meso\u2010level operational feasibility and micro\u2010level behavioural outcomes. Service design characteristics such as venue, day of week, prior publicity, service provider, and direct and indirect dissemination of results all may impact on outcomes. Future studies should consider cost\u2013benefit analyses of community and event\u2010based testing and context\u2010appropriate macro, meso and micro\u2010level evaluations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14231","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T03:25:32Z","timestamp":1581045932000},"page":"420-428","source":"Crossref","is-referenced-by-count":72,"title":["City checking: Piloting the UK's first community\u2010based drug safety testing (<i>drug checking<\/i>) service in 2 city centres"],"prefix":"10.1111","volume":"86","author":[{"given":"Fiona","family":"Measham","sequence":"first","affiliation":[{"name":"Chair in Criminology, Department of Sociology, Social Policy and Criminology University of Liverpool, UK, and Honorary Professor, RMIT  Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.06.004"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.304187"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031914-122957"},{"key":"e_1_2_10_5_1","unstructured":"Office for National Statistics (ONS).Deaths related to drug poisoning in England and Wales: 2018 registrations. Statistical Bulletin.2019.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/bulletins\/deathsrelatedtodrugpoisoninginenglandandwales\/2018registrations"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30209-3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30301-3"},{"key":"e_1_2_10_8_1","volume-title":"Reducing Crime and Preventing Harm: West Midlands Drug Policy Recommendations","author":"Jamieson D","year":"2018"},{"key":"e_1_2_10_9_1","volume-title":"Drug Safety Testing at Festivals and Nightclubs","author":"Royal Society for Public Health (RSPH)","year":"2017"},{"key":"e_1_2_10_10_1","unstructured":"Hansard.\u2018Music Festivals: Drug Safety Testing\u2019 Parliamentary adjournment debate.2018; 644 column 677. 6 July.http:\/\/bit.ly\/2lYhbDB"},{"key":"e_1_2_10_11_1","volume-title":"Drugs Policy, First Report of Session 2019\u201320. HC 143","author":"House of Commons Health and Social Care Committee (HoC)","year":"2019"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1609406917741796"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.018"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.10.001"},{"key":"e_1_2_10_15_1","volume-title":"Research Handbook on International Drug Policy","author":"Measham F","year":"2020"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13194"},{"key":"e_1_2_10_17_1","volume-title":"Global review of drug checking services operating in 2017. Drug Policy Modelling Program Bulletin No. 24","author":"Barratt M","year":"2018"},{"key":"e_1_2_10_18_1","volume-title":"Monitoring illicit psychostimulants and related health issues","author":"Brunt T","year":"2012"},{"key":"e_1_2_10_19_1","volume-title":"Drug checking as a harm reduction tool for recreational drug users: opportunities and challenges. Background paper commissioned by the EMCDDA for Health and social responses to drug problems: a European guide","author":"Brunt T","year":"2017"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.323"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1610"},{"key":"e_1_2_10_22_1","volume-title":"An inventory of on\u2010site pill\u2010testing interventions in the EU","author":"Kriener H","year":"2001"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.11.001"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.03.003"},{"key":"e_1_2_10_25_1","volume-title":"Pill testing, Ecstasy and Prevention. A scientific evaluation in three European cities","author":"Benschop A","year":"2002"},{"key":"e_1_2_10_26_1","volume-title":"Check your pills. Check your life. ChEck it!! High quality on\u2010site testing of illicit substances. Information counselling and safer use measures at raves in Austria [Internet]","author":"Kriener H","year":"2002"},{"key":"e_1_2_10_27_1","unstructured":"Makkai T. Macleod M. Vumbaca G.Hill P. Caldicott D. Noffs M. Tzanetis S.andHansen F. Report on the ACT GTM Pill Testing Pilot: A Harm Reduction Service. Harm Reduction Australia2018."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2608"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.17269\/s41997-018-0126-6"},{"key":"e_1_2_10_30_1","first-page":"2015","volume-title":"\u201cStart Small, Take it Easy\u201d. Results from the ANKORS Harm Reduction Survey at the 2013 Shambhala Music Festival","author":"Michelow W"},{"key":"e_1_2_10_31_1","volume-title":"ACT Pill Testing Trial 2019: Program Evaluation","author":"Olsen A","year":"2019"},{"key":"e_1_2_10_32_1","volume-title":"Harm Reduction and Drug Checking: A wrap\u2010around service for festivals. Case Study: Shambhala Music Festival\/ANKORS Drug Checking Harm Reduction, Service data 2015","author":"Sage C","year":"2015"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117715596"},{"key":"e_1_2_10_34_1","volume-title":"Evidence Brief: Drug checking services as a harm reduction intervention. Ontario Agency for Health Protection and Promotion (Public Health Ontario)","author":"Leece P","year":"2017"},{"issue":"46","key":"e_1_2_10_35_1","first-page":"1","article-title":"Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver","volume":"15","author":"Karamuzian M","year":"2018","journal-title":"Canada Harm Reduction J"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.07.007"},{"key":"e_1_2_10_37_1","unstructured":"Knox A.(2019) 2018\/2019 Results Know Your Stuff NZ. Online at:https:\/\/knowyourstuff.nz\/2018-19-results\/"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.08.007"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12936"},{"issue":"16","key":"e_1_2_10_40_1","first-page":"1","article-title":"Drug checking: a prevention measure for a heterogeneous group with high consumption frequency and polydrug use \u2010 evaluation of Zurich's drug checking services","volume":"8","author":"Hungerbuehler I","year":"2011","journal-title":"Harm Reduct J"},{"key":"e_1_2_10_41_1","volume-title":"The Temporary Autonomous Zone","author":"Bey H","year":"1991"},{"key":"e_1_2_10_42_1","volume-title":"Night Lives","author":"Fisher H","year":"2018"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62353-7"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02837.x"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040774"},{"key":"e_1_2_10_46_1","first-page":"2019","volume-title":"Annual Report 2018","author":"Drugs Information and Monitoring System (DIMS)"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0208-z"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12576"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.06.018"},{"key":"e_1_2_10_50_1","unstructured":"Whitmore C. Jones G. Measham F.andMosely J.ASAP Mass Spectrometry for the Real\u2010Time Identification of Psychoactive Drugs Supplied by the Public as Part of a Harm\u2010Reduction Service WOC Proceedings of the 67th ASMS Conference on Mass Spectrometry and Allied Topics Atlanta USA: June 2019 p.52.https:\/\/asms.org\/docs\/default-source\/Past-Annual-Conference-Programs\/67th_asms_program2019_4-19web.pdf?sfvrsn=0"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.9b00302"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T20:31:45Z","timestamp":1693859505000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/bcp.14231"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14231","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]}}}